<button id="vurnn"><object id="vurnn"></object></button>
  1. <th id="vurnn"></th>
    <button id="vurnn"></button>

  2. Pipeline

    Products under development

    Treatment
    field
    Pipeline source of technology Mechanism Target
    indication
    Preclinical
    studies
    IND
    Declaration
    Clinical Trial
    PhaseⅠ
    Clinical Trial
    Phase Ⅱ
    Clinical Trial
    Phase Ⅲ
    rights
    interests
     
    Metabolic diseases PB-119 Independent R D a long-acting GLP-1 receptor agonist type 2 diabetes mellitus
    Global
    Metabolic diseases PB-2301 Independent R D a long-acting GLP-1/GIP receptor agonist type 2 diabetes mellitus
    Global
    Metabolic diseases PB-2309 Independent R D a long-acting GLP-1/GIP/GCPreceptor agonist type 2 diabetes mellitus
    Metabolic diseases PB-718 Independent R D a dual agonist that activates both the GLP-1 receptor and the glucagon receptor nonalcoholic fatty liver disease
    Global
    Metabolic diseases PB-119 Independent R D a long-acting GLP-1 receptor agonist overweight or obesity
    Global
    Metabolic diseases PB-718 Independent R D a dual agonist that activates both the GLP-1 receptor and the glucagon receptor overweight or obesity
    Global
    Gastrointestinal diseases PB-1902 Independent R D the only oral opioid receptor antagonist for the treatment of opioid-induced constipation (OIC) opioid-induced constipation
    Global
    other Metabolic diseases PB-722 Independent R D GCG receptor agonist a novel drug for congenital hyperinsulinemia
    Global

    Product development strategy

    午夜福利卡一卡二卡三卡四,黑人VIDEO粗暴亚裔,黑人XXXX精品,黑人变态强奷长篇小说